SOURCE: Althea Technologies, Inc.

June 16, 2005 18:24 ET

Althea Founders Receive Ernst & Young's 2005 San Diego Entrepreneur Of The Year Award

SAN DIEGO,CA -- (MARKET WIRE) -- June 16, 2005 -- Althea Technologies, Inc., a leading provider of innovative technologies for pharmaceutical services and manufacturing, announced today that its founders, Dr. Francois Ferre and Dr. Magda Marquet were selected from a pool of distinguished nominees as the recipients of the Ernst & Young San Diego Regional 2005 Entrepreneur Of The Year® award in the Life Science category.

Drs. Ferre and Marquet, who serve as Co-President and Co-CEO, were selected for their strategic leadership and unwavering entrepreneurial vision.

"It is a great honor to receive this award," stated Dr. Ferre. "It is a testament to the success of Althea, and is a true measure of all the hard work and dedication put forth by every member of the Althea team." Dr. Marquet added, "The mission of our company, to enable the rapid development of innovative therapeutics and vaccines is highly challenging. It is immensely rewarding to be recognized for leading such a skilled and talented team of people."

Now in its 19th year, the Ernst & Young Entrepreneur of the Year award recognizes entrepreneurs who have demonstrated excellence in areas of such as innovation, financial performance and personal commitment to their business and communities. Ernst & Young honors individuals in 46 regions nationwide. The winners are selected by past winners, community business and civic leaders, and academicians. Finalists and winners of the national award will be announced in November 2005.

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing and development services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins and DNA-based therapeutics and vaccines, aseptic filling, and gene quantification using real-time PCR and gene expression analysis under GLP conditions. Additionally, Althea has introduced new services and technologies for the identification and understanding of gene signatures with innovative tools such as the company's proprietary eXpress Profiling™ technology. For more information, visit www.altheatech.com.

Contact Information


  • Contact:

    Althea Technologies, Inc.
    Alan Moore
    Executive Vice President and CBO
    (858) 882-0205
    Email Contact